Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends ELTX vs. NKTX, DMAC, GLTO, ATOS, CRBP, FBRX, GLSI, SGMT, CNTX, and GALTShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Nkarta (NKTX), DiaMedica Therapeutics (DMAC), Galecto (GLTO), Atossa Therapeutics (ATOS), Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Greenwich LifeSciences (GLSI), Sagimet Biosciences (SGMT), Context Therapeutics (CNTX), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical preparations" industry. Elicio Therapeutics vs. Nkarta DiaMedica Therapeutics Galecto Atossa Therapeutics Corbus Pharmaceuticals Forte Biosciences Greenwich LifeSciences Sagimet Biosciences Context Therapeutics Galectin Therapeutics Elicio Therapeutics (NASDAQ:ELTX) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends. Do analysts recommend ELTX or NKTX? Elicio Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 117.39%. Nkarta has a consensus target price of $17.50, suggesting a potential upside of 352.20%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Do insiders and institutionals have more ownership in ELTX or NKTX? 35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by insiders. Comparatively, 8.7% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, ELTX or NKTX? Elicio Therapeutics has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElicio Therapeutics$2.30M21.54-$35.19M-$6.83-0.67NkartaN/AN/A-$117.50M-$2.35-1.65 Which has more risk & volatility, ELTX or NKTX? Elicio Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Does the media prefer ELTX or NKTX? In the previous week, Elicio Therapeutics' average media sentiment score of 0.00 equaled Nkarta'saverage media sentiment score. Company Overall Sentiment Elicio Therapeutics Neutral Nkarta Neutral Does the MarketBeat Community believe in ELTX or NKTX? Nkarta received 51 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Elicio Therapeutics an outperform vote while only 76.00% of users gave Nkarta an outperform vote. CompanyUnderperformOutperformElicio TherapeuticsOutperform Votes685.71% Underperform Votes114.29%NkartaOutperform Votes5776.00% Underperform Votes1824.00% Is ELTX or NKTX more profitable? Nkarta's return on equity of -28.83% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elicio TherapeuticsN/A -555.45% -157.42% Nkarta N/A -28.83%-22.53% SummaryNkarta beats Elicio Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Banyan Hill PublishingBillionaires Spot Once-In-25-Year Wealth OpportunityWhy November 7th Will Impact Stocks More Than The Election Just 48 hours after the 2024 Presidential Election… A man from a completely different government branch is going to stand up, say a few words… and make history in the stock market. Click here for the full story. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.54M$7.15B$5.48B$8.47BDividend YieldN/A8.78%5.22%4.11%P/E Ratio-0.6724.06143.7719.67Price / Sales21.54262.731,142.6775.27Price / CashN/A48.2338.5033.66Price / Book3.415.784.784.58Net Income-$35.19M$159.62M$121.45M$228.13M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics2.0082 of 5 stars$4.60-3.8%$10.00+117.4%-21.7%$49.54M$2.30M-0.67N/ANKTXNkarta2.3953 of 5 stars$3.87-7.0%$17.50+352.2%+110.9%$191.24MN/A-1.93140Positive NewsDMACDiaMedica Therapeutics1.4426 of 5 stars$4.38+1.9%$7.00+59.8%+99.1%$187.21MN/A-8.2620GLTOGalecto2.3981 of 5 stars$6.86flat$10.00+45.9%-51.9%$185.86MN/A-0.2940Gap UpATOSAtossa Therapeutics1.4394 of 5 stars$1.46-2.7%$6.25+328.1%+121.2%$183.61MN/A-6.958News CoverageCRBPCorbus Pharmaceuticals4.2133 of 5 stars$16.59-5.0%$65.86+297.0%+186.5%$177.30M$880,000.00-2.8640FBRXForte Biosciences1.7781 of 5 stars$4.83+1.7%$3.25-32.7%+24,050.0%$176.02MN/A-0.265Gap UpGLSIGreenwich LifeSciences1.7905 of 5 stars$13.59-1.5%$38.00+179.6%+74.9%$175.04MN/A-17.203News CoverageSGMTSagimet Biosciences2.6086 of 5 stars$5.65-4.2%$24.00+324.8%+24.4%$173.29M$2M0.008CNTXContext Therapeutics2.4848 of 5 stars$2.23+11.5%$6.25+180.3%+102.7%$167.25MN/A-2.107Gap UpHigh Trading VolumeGALTGalectin Therapeutics2.5102 of 5 stars$2.58-1.5%$11.00+326.4%+29.0%$162.83MN/A-3.279Positive News Related Companies and Tools Related Companies NKTX Competitors DMAC Competitors GLTO Competitors ATOS Competitors CRBP Competitors FBRX Competitors GLSI Competitors SGMT Competitors CNTX Competitors GALT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELTX) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELTX Stock Alerts